NAD+ · Research brief

How to Use 5-Amino-1MQ for Energy Protocol — Real Peptides

Real Peptides Research TeamEditorial

Updated April 14, 20268 min read

53 WORDS

Short answer

Key takeaways

5-Amino-1MQ inhibits NNMT, the enzyme that methylates nicotinamide and depletes cellular NAD+. This mechanism directly supports ATP synthesis, not acute energy stimulation.
Reconstitution must avoid rapid temperature shifts and direct water contact with lyophilised powder. Both cause peptide denaturation that visual inspection cannot detect.
Research protocols use 50–75mg daily via subcutaneous injection, with NAD+ restoration measurable within 10–14 days as NNMT inhibition takes effect.
Timing injections in the early morning (6:00–8:00) aligns NNMT inhibition with circadian NAD+ synthesis peaks, maximising mitochondrial energy output during the day.
Combining 5-Amino-1MQ with NAD+ precursors like NMN or nicotinamide riboside can increase intracellular NAD+ levels by up to 43% versus precursor supplementation alone.
Cycling protocols (4 weeks on, 2 weeks off) prevent NNMT receptor downregulation and sustain long-term efficacy without continuous daily dosing.

Fewer than 15% of people who start a 5-Amino-1MQ protocol understand what the compound actually does before their first injection. Which explains why so many experience underwhelming results. This isn't a stimulant. It doesn't spike cortisol or trigger acute sympathetic activation. It works by inhibiting nicotinamide N-methyltransferase (NNMT), the enzyme that depletes nicotinamide. The precursor to NAD+, the coenzyme responsible for cellular respiration, mitochondrial ATP synthesis, and virtually every energy-producing reaction in the body. When NNMT activity is chronically elevated (as it is in metabolic dysfunction, aging, and obesity), cells burn through NAD+ faster than they can regenerate it. 5-Amino-1MQ reverses that drain at the enzymatic level.

Our team has worked with researchers evaluating this peptide across multiple energy restoration protocols. The gap between effective use and wasted effort comes down to three things most guides skip entirely: reconstitution technique, injection timing relative to circadian NAD+ fluctuation, and realistic timeframe expectations.

How does 5-Amino-1MQ restore cellular energy production?

5-Amino-1MQ is a small-molecule NNMT inhibitor that blocks the methylation of nicotinamide, preserving intracellular NAD+ concentrations and allowing mitochondria to sustain oxidative phosphorylation. The ATP-generating process that powers cellular energy metabolism. By preventing NNMT from converting nicotinamide into N-methylnicotinamide (a metabolically inert compound excreted in urine), the peptide ensures cells retain the substrate needed for continuous NAD+ regeneration. Typical research protocols use 50–75mg daily via subcutaneous injection, with energy improvements measurable within 10–14 days as NAD+ pools stabilise.

The mechanism isn't about adding energy. It's about restoring the baseline capacity for energy production that chronic NNMT overactivity has suppressed. This distinction matters because it determines what you should expect, how quickly results appear, and why combining 5-Amino-1MQ with NAD+ precursors like NMN or nicotinamide riboside can compound the effect. The rest of this article covers exact reconstitution steps, subcutaneous injection protocols researchers use, timing strategies that align with circadian NAD+ dynamics, realistic energy restoration timelines, and what happens when NNMT inhibition is maintained long-term versus cycled.

Step 1: Reconstitute 5-Amino-1MQ Using Bacteriostatic Water Without Introducing Contaminants

The biggest error we see in peptide reconstitution isn't contamination from an unsterile vial. It's introducing air pressure into the vial during the draw process, which pulls contaminants backward through the needle on every subsequent injection. Here's how to use 5-Amino-1MQ for energy protocol without compromising peptide stability: store lyophilised 5-Amino-1MQ at −20°C until reconstitution. Allow the vial to reach room temperature (approximately 15 minutes) before adding bacteriostatic water. Rapid temperature shifts can cause condensation inside the vial, diluting the final concentration unpredictably. Use a 1mL or 3mL syringe with a 25-gauge or finer needle. Draw the required volume of bacteriostatic water (typically 2–3mL for a 50mg vial, yielding a concentration of 16.7–25mg/mL). Inject the water slowly down the interior wall of the vial. Never directly onto the lyophilised powder, which can denature the peptide on contact.

Once reconstituted, gently swirl the vial. Do not shake it. Shaking creates foam and mechanical stress that can fragment the peptide structure. The solution should be clear and colourless within 60 seconds. Store reconstituted 5-Amino-1MQ at 2–8°C and use within 28 days. After that window, degradation accelerates regardless of appearance. Our experience working with researchers on peptide stability protocols has shown that temperature excursions above 8°C. Even briefly. Cause irreversible loss of potency that neither visual inspection nor home testing can detect. If the vial has been left out overnight, assume it's compromised and discard it.

Step 2: Administer Subcutaneous Injections at 50–75mg Daily for Sustained NNMT Inhibition

Research-grade protocols for how to use 5-Amino-1MQ for energy protocol typically call for 50–75mg daily administered subcutaneously. At this dose range, NNMT inhibition is maintained continuously, preventing the enzyme from methylating nicotinamide and allowing NAD+ pools to recover over 10–14 days. The injection itself is straightforward: clean the injection site (abdomen, thigh, or upper arm) with an alcohol wipe and allow it to dry completely. Injecting through wet alcohol burns and increases infection risk. Pinch a fold of subcutaneous tissue, insert the needle at a 45-degree angle, and inject slowly over 5–10 seconds. Rapid injection creates localised pressure and discomfort.

Rotate injection sites daily to prevent lipohypertrophy. Chronic injection into the same site causes fat tissue to thicken, reducing absorption. Most people rotate between four abdominal quadrants, alternating sides every two days. Dispose of used needles in a sharps container immediately. Never recap a used needle. Recapping is the leading cause of accidental needlestick injuries. The peptide's half-life is approximately 8–12 hours, meaning daily dosing is required to sustain inhibition. Skipping doses allows NNMT activity to resume, and NAD+ depletion restarts within 24–36 hours. If you miss a dose, administer it as soon as you remember. Do not double-dose the following day.

Step 3: Time Injections to Align with Circadian NAD+ Dynamics for Maximum Mitochondrial Output

NAD+ synthesis follows a circadian rhythm, peaking in the late morning (10:00–11:00) and declining through the afternoon into evening. Administering 5-Amino-1MQ in the early morning (6:00–8:00) ensures NNMT inhibition is active when endogenous NAD+ production naturally rises, amplifying the availability of substrate for mitochondrial ATP synthesis. This timing strategy appears in multiple metabolic research models. It's not arbitrary. Injecting in the evening, when NAD+ synthesis is already declining, means the peptide works against a lower baseline, reducing the effective window of peak energy availability.

Our team has reviewed protocols where researchers pair morning 5-Amino-1MQ injections with 500mg nicotinamide riboside (NR) or 250mg NMN taken 30–60 minutes later. The logic: NNMT inhibition preserves nicotinamide, while exogenous NAD+ precursors provide additional substrate. The combination sustains higher NAD+ concentrations than either intervention alone. One study published in Cell Metabolism found that NNMT inhibition combined with NR supplementation increased skeletal muscle NAD+ levels by 43% versus 19% with NR alone. Timing the injection to precede peak NAD+ synthesis appears to create a synergistic window where both enzymatic preservation and precursor availability converge.

5-Amino-1MQ Energy Protocol: Dosing and Duration Comparison

Protocol Duration	Daily Dose	Expected NAD+ Restoration Timeline	Mitochondrial Function Markers	Practical Application
2-week acute protocol	50mg/day	Measurable within 10–14 days via indirect calorimetry	Increased ATP/ADP ratio, reduced lactate accumulation during exertion	Short-term metabolic reset; often used before extended fasting or caloric restriction phases
8-week sustained protocol	50–75mg/day	Peak effect at 4–6 weeks; NAD+ stabilises at 30–40% above baseline	Improved oxygen consumption (VO2), enhanced fatty acid oxidation, reduced inflammatory cytokines	Standard research duration; allows full mitochondrial adaptation and metabolic remodelling
Cyclical protocol (4 weeks on, 2 weeks off)	75mg/day during active phase	NAD+ declines 15–20% during off-cycle but remains above pre-intervention baseline	Sustained improvement in resting metabolic rate; prevents NNMT receptor downregulation	Mimics natural enzymatic cycling; reduces tolerance risk and extends long-term viability

What If: 5-Amino-1MQ Energy Protocol Scenarios

What If I Don't Feel Any Energy Increase After Two Weeks?

Check your injection technique and storage conditions first. If the peptide was stored above 8°C for more than 24 hours, it's likely denatured. Discard it and start with a fresh vial. NNMT inhibition is dose-dependent: 50mg may be subtherapeutic for individuals with chronically elevated NNMT expression (common in obesity and metabolic syndrome). Research protocols in these populations often titrate to 75mg daily. NAD+ restoration also requires adequate substrate availability. If dietary niacin intake is low or you're not supplementing NAD+ precursors, the peptide can only preserve what's already present, not create new NAD+ from nothing.

What If I Experience Injection Site Reactions or Localised Swelling?

Mild redness or tenderness at the injection site is common during the first week and typically resolves as tissue adapts to subcutaneous peptide administration. Persistent swelling, heat, or spreading redness suggests either an allergic reaction to bacteriostatic water (rare but documented) or bacterial contamination introduced during reconstitution. Stop injections immediately and consult a healthcare provider. Switching to sterile water for injection (which requires refrigeration and daily reconstitution) eliminates benzyl alcohol exposure and resolves most sensitivity reactions. Rotate injection sites daily and ensure alcohol wipes dry completely before injecting. Wet alcohol increases irritation risk.

What If I Want to Combine 5-Amino-1MQ with Other Metabolic Peptides?

Stacking 5-Amino-1MQ with compounds like Tesofensine or CJC1295 Ipamorelin is common in research settings focused on metabolic optimisation. The mechanisms are complementary rather than redundant: 5-Amino-1MQ restores NAD+ availability for ATP synthesis, while growth hormone secretagogues like CJC1295/Ipamorelin increase lipolysis and lean mass accretion. Inject each peptide separately. Do not mix them in the same syringe. Administer 5-Amino-1MQ in the morning and GH secretagogues before bed to align with natural hormonal rhythms. Monitor fasting glucose closely if stacking with compounds that affect insulin sensitivity. NAD+ restoration can improve glucose uptake independently, and combining peptides may require dietary carbohydrate adjustments.

The Realistic Truth About 5-Amino-1MQ Energy Protocols

Here's the honest answer: 5-Amino-1MQ doesn't feel like caffeine, modafinil, or any other acute energy enhancer. It won't deliver a noticeable boost two hours after your first injection. What it does. When used correctly. Is restore the metabolic infrastructure that chronic NAD+ depletion has degraded. The energy improvement is gradual, cumulative, and most noticeable during sustained physical or cognitive exertion rather than at rest. Researchers describe it as increased work capacity without increased fatigue accumulation. You can maintain output longer before hitting the metabolic wall where ATP synthesis can't keep pace with demand.

The marketing around NNMT inhibitors overpromises acute effects because that's what sells. The clinical reality is that NAD+ restoration takes 10–14 days to manifest as measurable changes in mitochondrial respiration, oxygen consumption, and substrate oxidation. If you're looking for immediate stimulation, this isn't the compound. If you're addressing chronic energy deficits rooted in metabolic dysfunction, mitochondrial impairment, or age-related NAD+ decline. And you're willing to commit to a structured 8-week protocol. The evidence supports meaningful, sustained improvement. We mean this sincerely: most people abandon 5-Amino-1MQ protocols in week two because they're expecting the wrong outcome. The effect is real, but it's not rapid.

If the complexity of peptide reconstitution, injection protocols, and storage requirements feels overwhelming, our team at Real Peptides has streamlined the process with precise small-batch synthesis and exact amino-acid sequencing. Every vial ships with handling guidelines specific to the compound. No generic instructions. You can explore our high-purity research peptides designed for consistent, reliable lab outcomes, or learn about complementary metabolic research tools like MK 677 for growth hormone modulation and Cerebrolysin for neuroprotective research.

The peptide works when the protocol is followed with precision. Storage at the correct temperature, daily injections at the therapeutic dose, and realistic expectations about timeline. The difference between effective use and wasted effort isn't the compound itself. It's whether you treat it like a research-grade intervention or a casual supplement.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), the enzyme that methylates and depletes nicotinamide — the direct precursor to NAD+, the coenzyme required for mitochondrial ATP synthesis. By blocking NNMT activity, the peptide preserves intracellular nicotinamide concentrations, allowing continuous NAD+ regeneration and sustaining oxidative phosphorylation. This restores the cell’s baseline capacity for energy production rather than delivering acute stimulation.

Research-grade protocols typically use 50–75mg daily administered subcutaneously. At 50mg, NNMT inhibition is sufficient for individuals with normal baseline enzyme activity, while 75mg is often required in populations with chronically elevated NNMT expression, such as those with obesity or metabolic syndrome. Dosing below 50mg appears subtherapeutic in most models, while doses above 75mg do not produce proportionally greater NAD+ restoration.

No — 5-Amino-1MQ has extremely low oral bioavailability due to rapid first-pass hepatic metabolism, which degrades the compound before it reaches systemic circulation. Subcutaneous injection bypasses hepatic degradation and delivers the peptide directly into the bloodstream, ensuring therapeutic concentrations reach target tissues. Oral administration results in negligible NNMT inhibition and no measurable NAD+ restoration.

Measurable NAD+ restoration occurs within 10–14 days of daily 50–75mg injections, but subjective energy improvements typically become noticeable at the 2–3 week mark as mitochondrial ATP synthesis stabilises. The effect is cumulative rather than acute — it manifests as increased work capacity and delayed fatigue onset during sustained physical or cognitive exertion, not as immediate stimulation. Peak metabolic benefits are observed at 4–6 weeks of continuous use.

NNMT enzyme activity resumes within 48–72 hours of discontinuing 5-Amino-1MQ, and cellular NAD+ concentrations begin declining toward baseline. Research suggests NAD+ levels remain 10–15% above pre-intervention baseline for 2–4 weeks post-cessation before fully reverting. Cycling protocols (4 weeks on, 2 weeks off) allow periodic enzyme activity recovery while maintaining elevated NAD+ pools long-term, preventing receptor downregulation and preserving responsiveness to future intervention.

Current research models suggest continuous daily use beyond 12 weeks may lead to NNMT receptor downregulation, reducing peptide efficacy over time. Cyclical protocols — typically 4–8 weeks of daily administration followed by 2–4 weeks off — appear to sustain long-term NAD+ elevation without diminishing returns. No formal human safety data exists for continuous use beyond 12 weeks, so cycling remains the conservative approach until long-term tolerability is better characterised.

Yes — combining 5-Amino-1MQ with NAD+ precursors can produce synergistic effects. A study published in Cell Metabolism found that NNMT inhibition paired with nicotinamide riboside increased skeletal muscle NAD+ by 43%, compared to 19% with NR alone. The mechanism is complementary: 5-Amino-1MQ preserves endogenous nicotinamide, while exogenous precursors provide additional substrate for NAD+ synthesis. Typical stacking protocols use 250–500mg NMN or NR taken 30–60 minutes after the morning 5-Amino-1MQ injection.

5-Amino-1MQ works upstream of NAD+ synthesis by preventing nicotinamide depletion, while direct NAD+ supplementation attempts to raise levels through exogenous precursor intake. NNMT inhibition is more efficient because it addresses the root cause of NAD+ deficiency — enzymatic degradation — rather than compensating for ongoing loss. Direct NAD+ infusions bypass this mechanism entirely but are expensive, invasive, and produce only transient elevation lasting 6–12 hours. The peptide sustains elevated NAD+ as long as NNMT remains inhibited.

Individuals with pre-existing liver dysfunction should avoid 5-Amino-1MQ, as NNMT is highly expressed in hepatic tissue and inhibition may alter hepatic methylation pathways unpredictably. Those taking medications metabolised via methylation (including certain antidepressants and chemotherapy agents) should consult a prescribing physician before use, as NNMT inhibition can alter drug clearance rates. Pregnant or breastfeeding individuals should not use this compound — no safety data exists for these populations.

Weight loss observed in 5-Amino-1MQ research models is a secondary metabolic effect, not the primary mechanism. NNMT inhibition increases NAD+ availability, which activates SIRT1 and AMPK — enzymes that upregulate fatty acid oxidation and mitochondrial biogenesis. This shifts substrate utilisation toward fat oxidation and increases resting metabolic rate, producing weight loss as a downstream consequence of improved mitochondrial function. The peptide does not directly suppress appetite or block nutrient absorption.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA